Citations

Clear

959 citation(s) found for "Service, F J".

Colonic Epithelial Circadian Disruption Worsens Dextran Sulfate Sodium–Induced Colitis
Jochum, Sarah B. , Shaikh, Maliha, Wilber, Sherry , Raeisi, Shohreh , Zhang, Lijuan , Song, Shiwen , Sanzo, Gabriella, Chouhan, Vijit , Ko, Frank C. , Post, Zoë , Tran, Laura , Ramirez, Vivian, Khazaie, Khashayarsha , Hayden, Dana M. , Brown, Mark J. F. , Voigt, Robin M. , Forsyth, Christopher B. , Swanson, Garth , Post, Zoe , Swanson, Garth R , Engen, Phillip A. , Naqib, Ankur D , Green, Stefan J. , Brown, Mark J, Keshavarzian, Ali

Mayo Clinic

Inflammatory Bowel Diseases | October 26, 2022 | Volume: 29 | Issue: 3 | Pages: 444-457

10.1093/ibd/izac219 | PMID 36287037 Get It

AbstractBackgroundDisruption of central circadian rhythms likely mediated by changes in microbiota and a decrease in gut-derived metabolites like short chain fatty acids (SCFAs) negatively impacts colonic barrier homeostasis. We aimed to explore the effects of isolated peripheral colonic circadian disruption on the colonic barrier in a mouse model of colitis and explore the mechanisms, including intestinal microbiota community structure and function.MethodsColon epithelial cell circadian rhythms were conditionally genetically disrupted in mice: TS4Cre-BMAL1lox (cBMAL1KO) with TS4Cre as control animals. Colitis was induced through 5 days of 2% dextran sulfate sodium (DSS). Disease activity index and intestinal barrier were assessed, as were fecal microbiota and metabolites.ResultsColitis symptoms were worse in mice with peripheral circadian disruption (cBMAL1KO). Specifically, the disease activity index and intestinal permeability were significantly higher in circadian-disrupted mice compared with control animals (TS4Cre) (P < .05). The worsening of colitis appears to be mediated, in part, through JAK (Janus kinase)-mediated STAT3 (signal transducer and activator of transcription 3), which was significantly elevated in circadian-disrupted (cBMAL1KO) mice treated with DSS (P < .05). Circadian-disrupted (cBMAL1KO) mice also had decreased SCFA metabolite concentrations and decreased relative abundances of SCFA-producing bacteria in their stool when compared with control animals (TS4Cre).ConclusionsDisruption of intestinal circadian rhythms in colonic epithelial cells promoted more severe colitis, increased inflammatory mediators (STAT3 [signal transducer and activator of transcription 3]), and decreased gut microbiota–derived SCFAs compared with DSS alone. Further investigation elucidating the molecular mechanisms behind these findings could provide novel circadian directed targets and strategies in the treatment of inflammatory bowel disease.
3D figure of epilepsy syndromes
Nabbout, Rima , Kuchenbuch, Mathieu , Cross, J. Helen , Wirrell, Elaine , Tinuper, Paolo , Cross, Helen J , Wirrell, Elaine C

Mayo Clinic

Epilepsia Open | October 22, 2022 | Volume: 8 | Issue: 1 | Pages: 217-220

10.1002/epi4.12665 | PMID 36271714 Get It

Abstract We propose an instructive figure that summarized the classification of epilepsy syndromes according to the 2022 report of the ILAE Task Force on Nosology and Definitions. Our aim is to present on the same figure different concepts such as the names of epilepsy syndromes, their extreme and classical ages of onset, their epilepsy types (generalized, focal, or generalized and focal) but also their membership in groups of epilepsy syndromes as for self‐limited or developmental and epileptic encephalopathies. With this figure, we provide an interactive tool, as supplementary data, helping to present this classification and link it to electro‐clinical mandatory, alerts, and exclusionary criteria of each syndrome, in accordance with the ILAE position papers on syndromes classification and nosology. This report may be used as an illustrative tool for teaching epilepsy syndromes and as a practical and comprehensive aid for the classification of epilepsy individuals' syndromes.
REFRACTIVE ERROR CHANGE DURING TREATMENT OF DIABETIC MACULAR EDEMA
Salabati, Mirataollah , Mahmoudzadeh, Raziyeh , Zhang, Qiang , Sharpe, James , Hsu, Jason , Regillo, Carl D. , Kuriyan, Ajay E. , Starr, Matthew R. , Kuriyan, Ajay E , Ho, Allen C.

Mayo Clinic

Retina | October 21, 2022 | Volume: 42 | Issue: 11 | Pages: 2059-2065

10.1097/iae.0000000000003583 | PMID 36269800 Get It

Purpose: To evaluate the impact of anti–vascular endothelial growth factor therapy on the refractive error in eyes with diabetic macular edema. Methods: Post hoc analysis of Diabetic Retinopathy Clinical Research protocol T. Spherical equivalent (SE) was calculated for study and fellow eyes at baseline, 1-year, and 2-year visits. The SE change of the eyes with edema was compared with those with resolved edema. The correlation between refractive error changes and central subfield thickness was evaluated. Results: Among 543 study eyes, SE changed from −0.17 (2.04) D at baseline visit to −0.16 (2.14) D at 2 years giving a hyperopic shift of 0.04 (0.82) D (P = 0.022). Among fellow eyes, mean (SD) SE changed from −0.19 (2.1) D at baseline to −0.11 (2.1) D at 2 years, giving a hyperopic shift of 0.12 (0.84) D (P = 0.001). No significant difference in SE shift was found between eyes with and without edema at 2 years in phakic (0.12D and 0.08 D, P = 0.87) and pseudophakic eyes (−0.24D and −0.08D, P = 0.30). The SE shift was not correlated with central subfield thickness change at the end of the second year (r = 0.02, P = 0.62). Conclusion: Diabetic macular edema patients have minimal changes in refractive error. The correction of refractive error may be considered during treatment, regardless of the presence of edema.
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
Martin, Ting , Sun, Yilun , Malone, Shawn , Roach, Mack , Dearnaley, David P. , Pisansky, Thomas M. , Feng, Felix Y. , Sandler, Howard M. , Efstathiou, Jason A. , Syndikus, Isabel , Hall, Emma , Tree, Alison , Sydes, Matthew R. , Cruickshank, Claire, Roy, Soumyajit , Bolla, M. , Reijke, Theo de, Nabid, Abdenour , Carrier, Nathalie , Souhami, Luís, Guerrero, A., Álvarez, A. , Segundo, Carmen González‐San , Maldonado, Xavier , Romero, Tahmineh , Steinberg, Michael L. , Valle, Luca , Nickols, Nicholas G. , Shoag, Jonathan E. , Reiter, Robert E. , Jia, Angela Y. , García, Jorge A. , Spratt, Daniel E. , Kishan, Amar U. , Ma, Ting Martin , Dearnaley, David , Hall, Emma C , Tree, Alison C , Bolla, Michel , Maingon, Philippe , Alvarez, Ana , Gonzalez San-Segundo, Carmen , Steinberg, Michael L , Valle, Luca F , Shoag, Jonathan E , Zaorsky, Nicholas G , Spratt, Daniel E , Kishan, Amar U , Sandler, Howard M , Efstathiou, Jason A , Zapatero, A. , Rettig, Matthew B. , Zaorsky, Nicholas G.

Mayo Clinic

Journal of Clinical Oncology | October 21, 2022 | Volume: 41 | Issue: 4 | Pages: 881-892

10.1200/jco.22.00970 | PMID 36269935 Get It

PURPOSE The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT). MATERIALS AND METHODS Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer–specific mortality. RESULTS Overall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points ( P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer–specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT. CONCLUSION ADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.
Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients
Lehrer, Eric J. , Gurewitz, Jason , Bernstein, Kenneth , Fakhoury, Kareem , Rusthoven, Chad G. , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Malouff, Timothy D. , Peterson, Jennifer , Bonney, Phillip A. , Hwang, Lindsay , Yu, Cheng , Zada, Gabriel , Deibert, Christopher P., Prasad, Rahul N. , Raval, Raju R. , Patel, Samir , Franzini, Andrea , Attuati, Luca , Mathieu, David , Trudel, Claire, Lee, Cheng-chia, Green, Sheryl , Ahluwalia, Manmeet S. , Sheehan, Jason P. , Peterson, Jennifer L., Mathieu, David , Ahluwalia, Manmeet S , Kondziolka, Douglas , Ruiz-García, Henry , Palmer, Joshua D. , Picozzi, Piero , Yang, Huai‐Che , Jones, Brianna M. , Trifiletti, Daniel M.

Mayo Clinic

Neurosurgery | October 18, 2022 | Volume: 91 | Issue: 6 | Pages: 872-882

10.1227/neu.0000000000002127 | PMID 36255215 Get It

BACKGROUND: Melanoma brain metastases are commonly treated with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs). However, the toxicity of these 2 treatments is largely unknown when administered concurrently. OBJECTIVE: To evaluate the risk of radiation necrosis (RN) with concurrent and nonconcurrent SRS and ICIs. METHODS: The guidelines from the Strengthening the Reporting of Observational Studies in Epidemiology checklist were used. Inverse probability of treatment weighting, univariable and multivariable logistic regression, and the Kaplan-Meier method was utilized. RESULTS: There were 203 patients with 1388 brain metastases across 11 international institutions in 4 countries with a median follow-up of 15.6 months. The rates of symptomatic RN were 9.4% and 8.2% in the concurrent and nonconcurrent groups, respectively ( P =.766). On multivariable logistic regression, V12 ≥ 10 cm 3 (odds ratio [OR]: 2.76; P =.006) and presence of BRAF mutation (OR: 2.20; P =.040) were associated with an increased risk of developing symptomatic RN; the use of concurrent over nonconcurrent therapy was not associated with an increased risk (OR: 1.06; P =.877). There were 20 grade 3 toxic events reported, and no grade 4 events reported. One patient experienced a grade 5 intracranial hemorrhage. The median overall survival was 36.1 and 19.8 months for the concurrent and nonconcurrent groups (log-rank P =.051), respectively. CONCLUSION: Concurrent administration of ICIs and SRS are not associated with an increased risk of RN. Tumors harboring BRAF mutation, or perhaps prior exposure to targeted agents, may increase this risk. Radiosurgical optimization to maintain V12 < 10 cm 3 is a potential strategy to reduce the risk of RN.
Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance
Ugarte‐Gil, Manuel F. , Alarcón, Graciela S. , Seet, Andrea M. , Izadi, Zara , Montgomery, Anna , Duarte‐García, Alí , Gilbert, Emily, Valenzuela-Almada, Maria O , Wise, Leanna , Sparks, Jeffrey A. , Hsu, Tiffany , Sirotich, Emily , Hausmann, Jonathan S. , Sufka, Paul , Grainger, Rebecca , Bhana, Suleman , Wallace, Zachary S. , Jacobsohn, Lindsay, Strangfeld, Anja , Mateus, Elsa F , Hyrich, Kimme L , Gossec, Laure , Lawson‐Tovey, Saskia , Kearsley‐Fleet, Lianne , Schaefer, Martin, Machado, Pedro , Schäfer, Martin , Ware, Anna , Gilbert, Emily L , Hsu, Tiffany Y-T , D'Silva, Kristin M , Patel, Naomi J , Sirotich, Emily , Liew, Jean , Hausmann, Jonathan S , Sufka, Paul , Grainger, Rebecca , Bhana, Suleman , Wallace, Zachary S , Strangfeld, Anja , Mateus, Elsa F , Hyrich, Kimme L , Gossec, Laure , Carmona, Loreto , Lawson-Tovey, Saskia , Kearsley-Fleet, Lianne , Schaefer, Martin , Machado, Pedro M , Robinson, Philip C , Gianfrancesco, Milena A , Yazdany, Jinoos , Alarcón, Graciela S. , Sparks, Jeffrey A , Duarte-García, Alí , Ugarte-Gil, Manuel F , Wise, Leanna M , Liew, Jean W. , Carmona, Loreto , Robinson, Philip C. , Yazdany, Jinoos

Mayo Clinic

Arthritis Care & Research | October 14, 2022 | Volume: 75 | Issue: 1 | Pages: 53-60

10.1002/acr.25039 | PMID 36239292 Get It

ObjectiveTo determine the association between race/ethnicity and COVID‐19 outcomes in individuals with systemic lupus erythematosus (SLE).MethodsIndividuals with SLE from the US with data entered into the COVID‐19 Global Rheumatology Alliance registry between March 24, 2020 and August 27, 2021 were included. Variables included age, sex, race, and ethnicity (White, Black, Hispanic, other), comorbidities, disease activity, pandemic time period, glucocorticoid dose, antimalarials, and immunosuppressive drug use. The ordinal outcome categories were: not hospitalized, hospitalized with no oxygenation, hospitalized with any ventilation or oxygenation, and death. We constructed ordinal logistic regression models evaluating the relationship between race/ethnicity and COVID‐19 severity, adjusting for possible confounders.ResultsWe included 523 patients; 473 (90.4%) were female and the mean ± SD age was 46.6 ± 14.0 years. A total of 358 patients (74.6%) were not hospitalized; 40 patients (8.3%) were hospitalized without oxygen, 64 patients (13.3%) were hospitalized with any oxygenation, and 18 (3.8%) died. In a multivariable model, Black (odds ratio [OR] 2.73 [95% confidence interval (95% CI) 1.36–5.53]) and Hispanic (OR 2.76 [95% CI 1.34–5.69]) individuals had higher odds of more severe outcomes than White individuals.ConclusionBlack and Hispanic individuals with SLE experienced more severe COVID‐19 outcomes, which is consistent with findings in the US general population. These results likely reflect socioeconomic and health disparities and suggest that more aggressive efforts are needed to prevent and treat infection in this population.
Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials
Lacy, Brian E. , Ford, Alexander C. , Bartolini, Wilmin , Shea, Elizabeth P., Bochenek, Wieslaw, Boinpally, Ramesh , Ford, Alexander C , Brenner, Darren M. , Wu, James X. , Almansa, Cristina

Mayo Clinic

American Journal of Gastroenterology | October 13, 2022 | Volume: 118 | Issue: 5 | Pages: 872-879

10.14309/ajg.0000000000002064 | PMID 36227782 Get It

INTRODUCTION: These post hoc analyses provide clinically relevant data concerning time to response for individual irritable bowel syndrome with constipation (IBS-C) symptoms after linaclotide use. METHODS: Time-to-response data were pooled from 4 randomized controlled trials. Response time for abdominal symptoms (pain, discomfort, and bloating) and complete spontaneous bowel movements (CSBMs) were analyzed using the Kaplan-Meier method; patients were categorized as early responders (≤4 weeks), late responders (>4–12 weeks), or nonresponders. RESULTS: Among 2,350 patients (1,172 placebo and 1,178 linaclotide 290 μg), >50% of patients with IBS-C who initiated linaclotide treatment experienced a decrease of ≥30% in abdominal pain, discomfort, or bloating within 3–4 weeks (median). The median time to achieving ≥3 CSBMs was 4 weeks. Although not all linaclotide-treated patients responded within 12 weeks, a late response occurred between 4 and 12 weeks in 1 in 6 patients for abdominal pain and in approximately 1 in 10 patients for CSBM frequency. Comparisons of early responders, late responders, and nonresponders for both response definitions indicated that women, Whites, and patients with less severe baseline abdominal symptoms were more likely to respond early. DISCUSSION: Although treatment responses with linaclotide occurred in >50% of patients with IBS-C within 4 weeks of treatment initiation, benefits for individual abdominal symptoms and/or CSBM frequency can still occur between 4 and 12 weeks. A lack of improvement in one symptom does not negate the possibility of response for others, highlighting the importance of discussing all symptoms with patients and not assuming treatment futility at 4 weeks.
Patient and Caregiver-Derived Health Service Improvements for Better Critical Care Recovery
Leggett, Nina , Hibbert, Elizabeth , Hall, Tarli, Boehm, Leanne M. , Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Eaton, Tammy L. , Harris, Wendy, Hope, Aluko A. , Jackson, James C. , Johnson, Annie, Kloos, Janet A. , Korzick, Karen , MacTavish, Pamela , Meyer, Joel , Montgomery-Yates, Ashley , Slack, Andrew, Wade, Dorothy , Still, Mary, Netzer, Giora, Hopkins, Ramona O., Iwashyna, Theodore J. , McPeake, Joanne , Sevin, Carla M. , Initiative, on behalf of the Society of Critical Care Medicine’s Thrive, Haines, Kimberley , Quasim, Tara , Mikkelsen, Mark E. , Initiative, on behalf of the Society of Critical Care Medicine’s Thrive

Mayo Clinic

Critical Care Medicine | October 7, 2022 | Volume: 50 | Issue: 12 | Pages: 1778-1787

10.1097/ccm.0000000000005681 | PMID 36205494 Get It

OBJECTIVES: To engage critical care end-users (survivors and caregivers) to describe their emotions and experiences across their recovery trajectory, and elicit their ideas and solutions for health service improvements to improve the ICU recovery experience. DESIGN: End-user engagement as part of a qualitative design using the Framework Analysis method. SETTING: The Society of Critical Care Medicine’s THRIVE international collaborative sites (follow-up clinics and peer support groups). SUBJECTS: Patients and caregivers following critical illness and identified through the collaboratives. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Eighty-six interviews were conducted. The following themes were identified: 1) Emotions and experiences of patients—“Loss of former self; Experiences of disability and adaptation”; 2) Emotions and experiences of caregivers—“Emotional impacts, adopting new roles, and caregiver burden; Influence of gender roles; Adaptation, adjustment, recalibration”; and 3) Patient and caregiver-generated solutions to improve recovery across the arc of care—“Family-targeted education; Expectation management; Rehabilitation for patients and caregivers; Peer support groups; Reconnecting with ICU post-discharge; Access to community-based supports post-discharge; Psychological support; Education of issues of ICU survivorship for health professionals; Support across recovery trajectory.” Themes were mapped to a previously published recovery framework (Timing It Right) that captures patient and caregiver experiences and their support needs across the phases of care from the event/diagnosis to adaptation post-discharge home. CONCLUSIONS: Patients and caregivers reported a range of emotions and experiences across the recovery trajectory from ICU to home. Through end-user engagement strategies many potential solutions were identified that could be implemented by health services and tested to support the delivery of higher-quality care for ICU survivors and their caregivers that extend from tertiary to primary care settings.
Inpatient Psychiatric Care for Children and Adolescents: Increasing the Integration of Service and Science
Patriquin, Michelle A. , Thompson, Alysha D. , Lowry, Kelly Walker, Leffler, Jarrod M. , Reynolds, Elizabeth K.

Mayo Clinic

Evidence-Based Practice in Child and Adolescent Mental Health | October 3, 2022 | Volume: 7 | Issue: 4 | Pages: 503-512

10.1080/23794925.2022.2127132 Get It

Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)
Shander, Aryeh , Corwin, Howard L., Meier, Jens , Bisbe, Elvira , Erhard, J., Faraoni, David , Farmer, Shannon L. , Hall, Tiffany , Hardy, Jean‐François, Hofmann, Axel , Lee, Cheuk‐Kwong, Leung, Tsin Wah, Ozawa, Sherri , Sathar, Jameela , Torres, Rosalio, Múñoz, Manuel , Auerbach, Michael , Blitz, Jeanna D. , Frank, Steven M. , Girelli, Domenico , Lee, Cheuk Kwong , Spahn, Donat R. , Warner, Matthew A.

Mayo Clinic

Annals of Surgery | September 22, 2022 | Volume: 277 | Issue: 4 | Pages: 581-590

10.1097/sla.0000000000005721 | PMID 36134567 Get It

Background: Perioperative anemia has been associated with increased risk of red blood cell transfusion and increased morbidity and mortality after surgery. The optimal approach to the diagnosis and management of perioperative anemia is not fully established. Objective: To develop consensus recommendations for anemia management in surgical patients. Methods: An international expert panel reviewed the current evidence and developed recommendations using modified RAND Delphi methodology. Results: The panel recommends that all patients except those undergoing minor procedures be screened for anemia before surgery. Appropriate therapy for anemia should be guided by an accurate diagnosis of the etiology. The need to proceed with surgery in some patients with anemia is expected to persist. However, early identification and effective treatment of anemia has the potential to reduce the risks associated with surgery and improve clinical outcomes. As with preoperative anemia, postoperative anemia should be treated in the perioperative period. Conclusions: Early identification and effective treatment of anemia has the potential to improve clinical outcomes in surgical patients.